<DOC>
	<DOCNO>NCT01322178</DOCNO>
	<brief_summary>The aim study explore whether cetuximab combination mFOLFOX6 treatment could improve resection rate patient KRAS wild-type , unresectable liver metastasis mCRC .</brief_summary>
	<brief_title>Study Cetuximab Combination With mFOLFOX-6 ( Oxaliplatin , Leucovorin , 5-FU ) Treat Colorectal Liver Metastatic Cancer Patients</brief_title>
	<detailed_description>During last decade , chemotherapy metastatic colorectal cancer ( mCRC ) make considerable progress.However , approximately 25 % patient colorectal cancer present overt metastatic disease . In selected patient , synchronous metachronous liver metastasis ( LM ) resect curative intention . Over last 5 year recognition preoperative , neoadjuvant , combination chemotherapy regimens , namely , 5-fluorouracil/folinic acid ( 5-FU/FA ) combination either irinotecan oxaliplatin facilitate downsize initially unresectable LM make resection possible . The addition target therapy might render even effective . Due result , investigator hypothesize cetuximab combination mFOLFOX6 treatment patient KRAS wild-type , unresectable liver metastasis mCRC may improve clinical outcome .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Male female 1875 year age Performance status ( ECOG ) 0~1 Unresectable , histologically confirm , synchronous metachronous liver metastasis colorectal cancer . Unresectable liver metastasis define : patient five liver metastasis and/or Liver metastasis technically unresectable immediately , expect remain functional liver tissue ≥ 30 % resection . ( Patients evaluate multidisciplinary team three local surgeon one local radiologist , include surgical consultation potentially resectable patient basis remain liver volume , infiltration liver vein , infiltration liver artery , portal branch bile duct . ) Tumor tissue ( primary metastasis ) genotypologically classify KRAS wildtype codon 12 codon 13 KRAS gene exon 2 No prior chemotherapy ( except adjuvant chemotherapy interval ≥ 6 month ) Presence least one index lesion hepatic metastasis measurable CT scan MRI , irradiated area Neutrophils ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 8 g/dL Bilirubin level ≤ 1.0 x ULN AST ALT &lt; 1.5 x ULN Serum creatinine ≤ 1.0 x ULN Life expectancy ≥ 3 month Male female childbearing period effective contraception Signed write informed consent Any investigational agent ( ) within 4 week prior entry Previous exposure EGFRtargeting therapy Any evidence extrahepatic metastasis and/or primary tumor recurrence Total volume liver lesion &gt; 70 % Clinically relevant peripheral neuropathy Acute subacute intestinal obstruction history inflammatory bowel disease Breastfeeding pregnant woman , effective contraception risk conception exists ( male female patient 4 month end chemotherapy ) Previous malignancy ( except colorectal cancer , history basal cell carcinoma skin preinvasive carcinoma cervix adequate treatment ) Known drug abuse/ alcohol abuse Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Severe organ failure disease , include : clinically relevant coronary disease , cardiovascular disorder myocardial infarction within 12 month study entry , severe psychiatric illness , severe infection DIC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>colorectal carcinoma</keyword>
</DOC>